Cats with chronic pain conditions benefit enormously from multimodal pain management combining multiple drug classes and non-pharmacological approaches, reducing the risk of side effects while improving welfare.
Feline chronic pain management has historically lagged behind dogs due to the limited drug options available and the metabolism challenges of cat pharmacology. The consequence is that many cats with osteoarthritis, dental disease, or other chronic pain conditions receive either no pain management or inadequate single-drug therapy. The introduction of newer NSAID options and growing evidence for gabapentin efficacy has significantly expanded the multimodal toolkit. Environmental modification for arthritic cats - ramps, low-sided litter boxes, heated beds at floor level - provides welfare improvement without medication and is universally applicable. The reluctance to use long-term NSAIDs in cats with any concurrent kidney disease creates a clinical dilemma, as many elderly cats have both conditions; risk-benefit analysis under regular monitoring may support judicious NSAID use even in early renal disease. The principle of multimodal management - using lower doses of multiple agents - reduces side effect risk while improving overall pain control.